Variables | Recurrence | Overall survival | ||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
ALT (> 40 U/L versus ≤ 40 U/L) | 1.24 (0.78–1.96) | 0.369 | N.A. | N.A. |
AST (> 40 U/L versus ≤ 40 U/L) | 1.46 (0.93–2.27) | 0.099 | N.A. | N.A. |
AFP (> 400 ng/ml versus ≤ 400 ng/ml) | 1.94 (1.29–2.94) | 0.002 | N.A. | N.A. |
No. of tumors (multi versus single) | 4.71 (1.28–17.42) | 0.020 | N.A. | N.A. |
Tumor size (> 5 cm versus ≤ 5 cm) | 2.01 (1.29–3.13) | 0.002 | N.A. | N.A. |
Macrovascular invasion (yes versus no) | 3.19 (0.83–12.29) | 0.092 | 1.59 (0.95–2.67) | 0.078 |
Microvascular invasion (yes versus no) | 1.18 (0.75–1.85) | 0.471 | 1.86 (1.16–2.96) | 0.009 |
Edmondson stage (III–IV versus I–II) | 1.33 (0.88–2.02) | 0.182 | 0.98 (0.60–1.61) | 0.932 |
ALBI grade (II versus I) | 1.51 (0.63–3.60) | 0.355 | 1.89 (1.09–3.18) | 0.021 |
CD73 (high versus low) | 2.82 (1.87–4.26) | < 0.001 | 3.35 (2.01–5.52) | < 0.001 |